The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute provide funding and drug development support of research efforts that aim to treat or prevent Alzheimer’s disease, related dementias and cognitive-decline associated with aging. Each year up to two ADDF-Harrington Scholars are chosen. The award includes:
- Two-year grant
- Funding up to $600,000
- Drug development expertise and project management support
- A personalized team of drug developers and project manager for each award recipient
- Expert business, commercialization and clinical development advice
- Regulatory assistance
- Intellectual property (IP) review and advice
- Assistance identifying and securing additional financial support based on project needs
Join our emailing list to become a part of our community and receive periodic communications about grant funding opportunities, as well as news and updates.
- MD or PhD (or equivalent)
- Faculty position at an accredited academic medical center, university or research institution in the US, Canada or the UK, and conduct the majority of his/her/their research at that institution
- Proposals should support the development of a therapeutic that could treat, prevent, or slow Alzheimer’s disease or related dementias
- A project must have only a single Principal Investigator (PI), who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
- Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.
Late submissions will not be accepted for any reason, other than issues with the Harrington Discovery Institute’s submission system. Proposals received after the deadline will not be reviewed.
The ADDF-Harrington Scholar award selection committee seeks breakthrough discoveries that demonstrate innovation, creativity and potential for clinical impact, including:
- Discoveries deemed to address unmet medical needs
- Modulators of novel targets
- Potential to be developed into a commercial program
- Strong intellectual property (IP) or protection strategy
- May be either a small molecule, biologic, or other therapeutic modality
- Diagnostics or devices only acceptable as part of a therapeutic development project
- Call Opens for Letters of Intent (LOI)
June 1, 2022
- LOI Submission Deadline (EXTENDED)
July 25, 2022
- Full Application Deadline for those Invited
October 24, 2022
- Announce 2022 ADDF-Harrington Scholars
How to Apply Apply Now